Diabetes Mellitus and Transplantation: Risks for Post-transplant Diabetes

  • Phuong-Thu T. Pham
  • Phuong-Mai T. Pham
  • Alan H. Wilkinson
Chapter

Abstract

New onset diabetes mellitus after transplantation (NODAT) is a serious and frequently observed complication following solid organ transplantation. Kidney transplant recipients who develop NODAT are at increased risk of fatal and non-fatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Identification of high-risk patients and implementation of measures to reduce the development of NODAT may improve long-term patient and graft outcome. The following chapter presents an overview of the literature on the current diagnostic criteria for NODAT, its incidence after solid organ transplantation, suggested risk factors, and potential pathogenic mechanisms. The impact of NODAT on patient and allograft outcomes and suggested guidelines for early identification and management of NODAT will also be discussed.

Keywords

Obesity Corticosteroid Cyclosporine Proteinuria Triglyceride 

References

  1. 1.
    Davidson J, Wilkinson AH, Dantal J et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 2003;7:SS3–SS24.CrossRefGoogle Scholar
  2. 2.
    Wilkinson AH, Davidson J, Dotta F et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291–298.CrossRefPubMedGoogle Scholar
  3. 3.
    Montori VM, Velosa JA, Basu A et al. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002;25:583–592.CrossRefPubMedGoogle Scholar
  4. 4.
    Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066–1072.CrossRefPubMedGoogle Scholar
  5. 5.
    Knobbler H, Stagnaro-Green A, Wallenstein S et al. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30–.CrossRefGoogle Scholar
  6. 6.
    Bigam D, Pennington J, Carpentier A et al. hepatitis-C related cirrhosis: a predictor of diabetes after orthotopic liver transplantation. Gastroenterology 2000;32:87.Google Scholar
  7. 7.
    Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation 2006;82:1667–1672.CrossRefPubMedGoogle Scholar
  8. 8.
    Pham PT, Danovitch GM, Pham PC. The medical management of the renal transplant recipient. In: Johnson RJ, John F (eds.), Comprehensive Clinical Nephrology, 3rd ed. Mosby, Philadelphia, PA, 2007, 1085–1101.Google Scholar
  9. 9.
    Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178–185.CrossRefPubMedGoogle Scholar
  10. 10.
    Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J AM Soc Nephrol 2005;16:3128–3135.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang N, Su D, Qu S et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function in transplants. Diabetes 2006;55:2429–2436.CrossRefPubMedGoogle Scholar
  12. 12.
    Hamer RA, Chow CL, Ong AC et al. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007;83:36–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Ducloux D, Motte G, Vautrin P et al. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant 1999;14:1244–1246.CrossRefPubMedGoogle Scholar
  14. 14.
    de Mattos AM, Olyaei AJ, Prather JC et al. Autosomal dominant polycystic kidney disease as a risk factor for diabetes mellitus following transplantation. Kidney Int 2005;67:714–720.CrossRefPubMedGoogle Scholar
  15. 15.
    Hjelmesaeth J. Hartmann: insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant 1999;14(10):2521–2522.CrossRefPubMedGoogle Scholar
  16. 16.
    Cosio FG, Pesavento TE, Osei K et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732–737.CrossRefPubMedGoogle Scholar
  17. 17.
    Hebert PL, Geiss LS, Tierney EF et al. Identifying persons with diabetes using Medicare claims data. Am J Qual 1999;14(6):270–277.CrossRefGoogle Scholar
  18. 18.
    Sulanc E, Lane JT, Puumala SE et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 2005;80(7):945–952.CrossRefPubMedGoogle Scholar
  19. 19.
    Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements for tacrolimus. Lancet 1996;348(9039):1446.CrossRefPubMedGoogle Scholar
  20. 20.
    Martinez-Castelao A, Hernandez MD, Pascual J et al. Detection and treatment of post kidney transplant hyperglycemia: A Spanish multicenter cross-sectional study. Transplant Proc 2005;37(9):3813–3816.CrossRefPubMedGoogle Scholar
  21. 21.
    Pham PT, Pham PC, Lipshutz G et al. New onset diabetes mellitus after transplantation. Endocrinol Metab Clin North Am 2007;36(4):873–890.CrossRefPubMedGoogle Scholar
  22. 22.
    Jindal RM, Revanur VK, Jardine AG. Immunosuppression and diabetogenicity. In: Hakim N, Stratta R, Gray D, (eds.), Pancreas and Islet Transplantation, 1st ed. Oxford University Press, New York, 2002, 247–275.Google Scholar
  23. 23.
    Hjelmesaeth J, Hartmann A, Kofstad J et al. Tapering off prednisolone and cyclosporine the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001;16:829–835.CrossRefPubMedGoogle Scholar
  24. 24.
    Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64(7):979–983.CrossRefPubMedGoogle Scholar
  25. 25.
    Midtvedt K, Hjemesaeth J, Hartmann A et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15(12): 3233–3239.CrossRefPubMedGoogle Scholar
  26. 26.
    Depcynski B, Daly B, Campbell LV et al. Predicting occurrence of diabetes mellitus in recipients of heart transplants. Diabetes Med 2000;17:15–19.CrossRefGoogle Scholar
  27. 27.
    Crutchlow MF, Bloom RD. transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol 2007;2:343–355.CrossRefPubMedGoogle Scholar
  28. 28.
    Van Hooff JP, Christiaans MHL, van Duijhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004;19(Suppl 6):vi18-vi12.Google Scholar
  29. 29.
    Venkatesan N, Davidson MB, Huchinson A. Possible role of the glucose-fatty acid cycle in dexamethasone-induced insulin antagonism in rats. Metabolism 1987;36: 883–891.CrossRefPubMedGoogle Scholar
  30. 30.
    Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3(5):590–598.CrossRefPubMedGoogle Scholar
  31. 31.
    Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562–2575.CrossRefPubMedGoogle Scholar
  32. 32.
    Heisel O, Heisel R, Balshaw R et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4(4):583–595.CrossRefPubMedGoogle Scholar
  33. 33.
    Meiser BM, Uberfuhr P, Fuchs A et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998;17:782–788.PubMedGoogle Scholar
  34. 34.
    Maes BD, Kuypers D, Messiaen T et al. Posttransplant diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72(10):1655–1661.CrossRefPubMedGoogle Scholar
  35. 35.
    Cai TH, Esterl RM, Nichols F et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. Transplant Proc 1998;30:1413–1414.CrossRefPubMedGoogle Scholar
  36. 36.
    Luan FL, Zhang H, Schaubel DE et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am J Transplant 2008;8:1871–1877.CrossRefPubMedGoogle Scholar
  37. 37.
    Bloom RD, Rao V, Weng F et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374–1380.CrossRefPubMedGoogle Scholar
  38. 38.
    Redmon JB, Olson LK, Armstrong MB et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98:2786–2793.CrossRefPubMedGoogle Scholar
  39. 39.
    Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68(3):396–402.CrossRefPubMedGoogle Scholar
  40. 40.
    Subramanian S, Trence DL. Immunosuppression agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007;36:891–905.CrossRefPubMedGoogle Scholar
  41. 41.
    Bonato V, Barni R, Cataldo D et al. Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc 2008;40(6):1888–1890.CrossRefPubMedGoogle Scholar
  42. 42.
    Kissebah AH, Vydelingum N, Murray R et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54(2):254–260.CrossRefPubMedGoogle Scholar
  43. 43.
    Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutrition Soc 2007;66:82–95.CrossRefGoogle Scholar
  44. 44.
    Kuypers DR, Claes K, Bammens B et al. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus. Nephrol Dial Transplant 2008;23:2033–2042.CrossRefPubMedGoogle Scholar
  45. 45.
    Myslak M, Amer H, Morales P et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006;6:1660–1665.CrossRefPubMedGoogle Scholar
  46. 46.
    Cosio FG, Kudva Y, van der Velde M, Larson TS et al. New onset hyperglycemia and diabetes mellitus are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67(6):2415–2421.CrossRefPubMedGoogle Scholar
  47. 47.
    Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Kidney Transplant 2006;6:2232–2237.CrossRefGoogle Scholar
  48. 48.
    Delgado-Borrego A, Casson D, Schoenfeld D et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004;77:703–710.CrossRefPubMedGoogle Scholar
  49. 49.
    Simo R, Lecube A, Genesca J et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29:2462–2466.CrossRefPubMedGoogle Scholar
  50. 50.
    Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after α-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003;14:2092–2098.CrossRefPubMedGoogle Scholar
  51. 51.
    Lehr H, Jao S, Waltzer WC et al. Cytomegalovirus-induced diabetes mellitus in a renal transplant recipient. Transplant Proc 1985;17:2152–2154.PubMedGoogle Scholar
  52. 52.
    Hjelmesaeth J, Sagedal S, Hartmannn A et al. Asymptomatic cytomegalovirus infection is associated with increased risk for new-onset diabetes and impaired insulin release after renal transplantation. Diabetologica 2004;47(9):1550–1556.CrossRefGoogle Scholar
  53. 53.
    Hjelmesaeth J, Muller F, Jenssen T et al. Is there a link between cytomegalovirus infection and new-onset posttransplant diabetes mellitus? Potential mechanisms of virus induced β-cell damage. Nephrol Dial Transplant 2005;20:2311–2315.CrossRefPubMedGoogle Scholar
  54. 54.
    Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603–611.CrossRefPubMedGoogle Scholar
  55. 55.
    Hjelmesaeth J, Hartmann A, Leivestad T et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006;69:588–595.CrossRefPubMedGoogle Scholar
  56. 56.
    Boudreaux JP, McHugh L, Canafax DM et al. The impact of cyclosporine and combination immunosuppression on the incidence of post transplant diabetes in renal allograft recipients. Transplantation 1987;44(3):376–387.CrossRefPubMedGoogle Scholar
  57. 57.
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;12(Suppl 1):34–41.Google Scholar
  58. 58.
    Pham PT, Pham PC. Assessing the risk of post-transplantation diabetes mellitus with an oral glucose tolerance test. Nat Clin Pract Nephrol 2008;4(11):600–601.CrossRefPubMedGoogle Scholar
  59. 59.
    Mannon RB. Therapeutic management of posttransplant diabetes mellitus. Transplant Rev 2008;22:116–124.CrossRefGoogle Scholar
  60. 60.
    Gerstein HC, Miller ME, Bigger T et alFor The Action to Control cardiovascular Risk in Diabetes Study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545–2559.CrossRefPubMedGoogle Scholar
  61. 61.
    Kraus RM, Eckel RH, Howard B et al. AHA dietary guidelines revision 2000: a statement for healthcare professionals from the nutrition committee of the American Heart Association. Circulation 2000;102:2284–2299.Google Scholar
  62. 62.
    Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabetes Metab 2004;30(6):487–496.CrossRefPubMedGoogle Scholar
  63. 63.
    Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355(15):1551–1562.CrossRefPubMedGoogle Scholar
  64. 64.
    Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000;70(Suppl 11):SS58-SS63.PubMedGoogle Scholar
  65. 65.
    Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172(2):213–226.PubMedGoogle Scholar
  66. 66.
    Kahn SE, Haffner SM, Heise MA. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy for the ADOPT study. NEJM 2006;355:2427–2443.CrossRefPubMedGoogle Scholar
  67. 67.
    Hampton T. Diabetes drugs tied to fractures in women. JAMA 2007;297:1645–1647.CrossRefPubMedGoogle Scholar
  68. 68.
    Srinivasan BT, Jarvis J, Khunti K et al. Recent advances in the management of type 2 diabetes mellitus: a review. Postgrad Med J 2008;84(996):524–531.CrossRefPubMedGoogle Scholar
  69. 69.
    Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003;43(6):649–660.PubMedGoogle Scholar
  70. 70.
    Niemi M, Backman JT, Neuvonen PJ et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000;68(5):495–500.CrossRefPubMedGoogle Scholar
  71. 71.
    Tartiana F, Faradji RN, Monroy K et al. Dapsone-induced artifactual A1C reduction in islet transplant recipients. Transplantation 2007;83(6):824.CrossRefGoogle Scholar
  72. 72.
    Pham PT, Pham PC, Danovitch GM. Posttransplant cardiovascular disease. Semin Nephrol 2007;27(4):430–444.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag US 2010

Authors and Affiliations

  • Phuong-Thu T. Pham
    • 1
  • Phuong-Mai T. Pham
    • 2
  • Alan H. Wilkinson
    • 1
  1. 1.Division of Nephrology, Department of Medicine, Kidney and Pancreas Transplant ProgramDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.David Geffen School of Medicine at UCLA, Sepulveda VA, Internal MedicineNorth HillsUSA

Personalised recommendations